Ann Smelkinson, MD
Internal Medicine · Cranbury, NJNPI 1487731972
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $356 and has fallen 70.5% since, to $105 in 2025.
Across 55 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$228
- AstraZeneca$129
- Axsome Therapeutics, Inc.$122
- Merck$108
- Pfizer$82
- Boehringer Ingelheim$76
- plus $237 from 10 others
What the payments were for
- Food & beverage$96298%
- Education$202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 11 | $228 |
| AstraZeneca | 9 | $129 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Merck | 8 | $108 |
| Pfizer | 6 | $82 |
| Boehringer Ingelheim | 6 | $76 |
| Bayer | 3 | $46 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Itamar Medical Inc | 1 | $26 |
| Johnson & Johnson | 2 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Abbott | 1 | $19 |
| Boston Scientific | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
How this compares
$981 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 15 | $25,457 |
| EliquisApixaban | 15 | $25,024 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $20,420 |
| MyrbetriqMirabegron | 13 | $6,621 |
| SynthroidLevothyroxine Sodium | 63 | $4,114 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $3,364 |
| Atorvastatin Calcium | 240 | $2,910 |
| Rosuvastatin Calcium | 220 | $2,893 |
| Levothyroxine Sodium | 218 | $2,696 |
| Losartan Potassium | 152 | $1,673 |
| Metformin Hcl ErMetformin Hcl | 116 | $1,626 |
| Bupropion XlBupropion Hcl | 38 | $1,501 |
| Amlodipine Besylate | 252 | $1,493 |
| Ipratropium Bromide | 24 | $1,458 |
| Nadolol | 11 | $1,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $76 | $25,45715 claims |
| PfizerEliquis | $82 | $25,02415 claims |
| MerckJanumet | $108 | $20,42014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Cranbury
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.